TY - JOUR
T1 - Increased prevalence of brain tumors classified as T2 hyperintensities in neurofibromatosis 1
AU - Griffith, Jennifer L.
AU - Morris, Stephanie M.
AU - Mahdi, Jasia
AU - Goyal, Manu S.
AU - Hershey, Tamara
AU - Gutmann, David H.
N1 - Funding Information:
J.L. Griffith reports no disclosures. S.M. Morris receives research support from NIH. J. Mahdi reports no disclosures. M.S. Goyal has received funding for travel and/or speaker honoraria from Bill and Melinda Gates Foundation and Yakult Bio-sciences Foundation and has participated in medicolegal cases. T. Hershey has received funding for travel and/or speaker honoraria from Pediatric Endocrine Society, Endocrine Society, International Wolfram Association, University of Alabama, and University of Pittsburgh; serves on the editorial board of Scientific Reports: Neuroscience; receives research support from NIH; and her spouse is author on patent re: novel formulation of drug and application and receives research support from Sage Pharmaceuticals and NIH. D.H. Gutmann is author on patents re: NF1 gene and protein; receives research support from US Department of Defense, NIH/NCI, The Giorgio Foundation, NF1-Dermal Neurofibroma Consortium, Children’s Tumor Foundation, and Neurofibromatosis Therapeutics Acceleration Program; receives license fee payments for technology re:TSC1 knockout mouse; and receives royalty payments from University of Michigan for NF1 gene patent. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/cp.
Funding Information:
This study was partially supported by an unrestricted gift from Schnuck Markets, Inc. (Dr. Gutmann) and the Neurologic Sciences Academic Development Award at Washington University School of Medicine under award K12 NS001690 (Dr. Morris).
Publisher Copyright:
© 2018 American Academy of Neurology.
PY - 2018/8/1
Y1 - 2018/8/1
N2 - Background We sought to define the radiologic features that differentiate neoplastic from non-neoplastic T2 hyperintensities (T2Hs) in neurofibromatosis type 1 (NF1) and identify those lesions most likely to require oncologic surveillance. Methods We conducted a single-center retrospective review of all available brain MRIs from 68 children with NF1 (n = 190) and 46 healthy pediatric controls (n = 104). All T2Hs identified on MRI were characterized based on location, border, shape, degree of T1 hypointensity, and presence of mass effect or contrast enhancement, and subsequently classified using newly established radiologic criteria as either unidentified bright objects (UBOs) or probable tumors. Lesion classification was pathologically confirmed in 10 NF1 cases. Results T2Hs were a highly sensitive (94.4%; 95% confidence interval [CI] 86.4%-98.5%) and specific (100.0%; 95% CI 92.3%-100.0%) marker for the diagnosis of NF1. UBOs constituted the majority of T2Hs (82%) and were most frequently located in cerebellar white matter, medial temporal lobe, and thalamus, where they were more likely than probable tumors to be bilateral (p < 0.001) and have nondiscrete borders (p < 0.001). Surprisingly, 57% of children with T2Hs harbored lesions classified as probable tumors, and 28% of children with probable tumors received treatment. In contrast to UBOs, probable tumors were most frequently located within the globus pallidus and medulla, and rarely occurred prior to 3 years of age. Conclusions With the implementation of standardized radiologic criteria, a high prevalence of brain tumors was identified in this at-risk population of children, of which nearly one-third required treatment, emphasizing the need for appropriate oncologic surveillance for patients with NF1 harboring nonoptic pathway brain tumors.
AB - Background We sought to define the radiologic features that differentiate neoplastic from non-neoplastic T2 hyperintensities (T2Hs) in neurofibromatosis type 1 (NF1) and identify those lesions most likely to require oncologic surveillance. Methods We conducted a single-center retrospective review of all available brain MRIs from 68 children with NF1 (n = 190) and 46 healthy pediatric controls (n = 104). All T2Hs identified on MRI were characterized based on location, border, shape, degree of T1 hypointensity, and presence of mass effect or contrast enhancement, and subsequently classified using newly established radiologic criteria as either unidentified bright objects (UBOs) or probable tumors. Lesion classification was pathologically confirmed in 10 NF1 cases. Results T2Hs were a highly sensitive (94.4%; 95% confidence interval [CI] 86.4%-98.5%) and specific (100.0%; 95% CI 92.3%-100.0%) marker for the diagnosis of NF1. UBOs constituted the majority of T2Hs (82%) and were most frequently located in cerebellar white matter, medial temporal lobe, and thalamus, where they were more likely than probable tumors to be bilateral (p < 0.001) and have nondiscrete borders (p < 0.001). Surprisingly, 57% of children with T2Hs harbored lesions classified as probable tumors, and 28% of children with probable tumors received treatment. In contrast to UBOs, probable tumors were most frequently located within the globus pallidus and medulla, and rarely occurred prior to 3 years of age. Conclusions With the implementation of standardized radiologic criteria, a high prevalence of brain tumors was identified in this at-risk population of children, of which nearly one-third required treatment, emphasizing the need for appropriate oncologic surveillance for patients with NF1 harboring nonoptic pathway brain tumors.
UR - http://www.scopus.com/inward/record.url?scp=85060334472&partnerID=8YFLogxK
U2 - 10.1212/CPJ.0000000000000494
DO - 10.1212/CPJ.0000000000000494
M3 - Article
C2 - 30140579
AN - SCOPUS:85060334472
SN - 2163-0402
VL - 8
SP - 283
EP - 291
JO - Neurology: Clinical Practice
JF - Neurology: Clinical Practice
IS - 4
ER -